Combined analysis of tumor tissue and ctDNA has shown that patients with any pathogenic variations in BRCA1, BRCA2, CDK12, TP53, PTEN, or RB1 experienced the shorter time to CRPC and that the accumulation of these variations increased a risk of developing CRPC. This evidence concerns the gene BRCA2 and neoplasm.